Exyte, Univercells fast track construction for COVID-19 vaccines

By The Science Advisory Board staff writers

May 14, 2020 -- High-tech construction firm Exyte and biomanufacturing company Univercells Technologies are partnering for construction of modular standardized and flexible manufacturing facilities for vaccines.

Rapid deployment of prefabricated plants will enable rapid mass production and shortened time-to-market for vaccines against SARS-CoV-2, according to the companies. The capital and operational expenditures will be dramatically reduced with the prefabricated solution. The concept is meant to be scalable for rapid capacity ramp-up and accelerated market entry to assist with providing vaccines for global immunization.

Through the partnership, Exyte's ExyCellR modular technology will be combined with Univercells' NevoLine biomanufacturing platform with a scale-X fixed-bed bioreactor. The modules can be adapted to any process layout for the production of vector-based and live attenuated vaccines.

Thermo Fisher to double viral vector manufacturing capacity
Thermo Fisher Scientific is expanding its viral vector development and manufacturing services with construction of a new commercial manufacturing site...
ABL Europe to manufacture Themis SARS-CoV-2 vaccine in France
Biopharmaceutical company Themis and contract development and manufacturing organization ABL Europe announced that they have signed an agreement to manufacture...
Exothera offers process development, viral vector support to biomanufacturers
Biomanufacturing company Univercells announced on March 19 that it has established a contract development and manufacturing organization named Exothera...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter